VI
CTKB icon

Versor Investments’s Cytek Biosciences CTKB Stock Holding History

Versor Investments’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-47,000
Closed -$305K – 748
2024
Q4 		$305K Buy
+47,000
New +$280K 0.05% 557
2024
Q3 		– Sell
-22,400
Closed -$125K – 798
2024
Q2 		$125K Sell
22,400
-24,500
-52% -$147K 0.02% 684
2024
Q1 		$315K Buy
+46,900
New +$371K 0.06% 483
2023
Q4 		– Sell
-33,900
Closed -$187K – 733
2023
Q3 		$187K Buy
+33,900
New +$272K 0.04% 597
2023
Q2 		– Sell
-12,100
Closed -$111K – 668
2023
Q1 		$111K Sell
12,100
-5,300
-30% -$57K 0.01% 675
2022
Q4 		$178K Buy
+17,400
New +$234K 0.02% 653

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Versor Investments's CTKB Position: Q1 2025 in Review

Versor Investments sold out of Cytek Biosciences (CTKB) in Q1 2025, closing a stake of 47,000 shares — an estimated $305K sold.

Versor Investments first reported a position in CTKB in Q4 2022 and held it in 6 quarters. The position peaked at $315K in Q1 2024. 160 funds tracked by Wall St. Rank hold CTKB as of Q1 2025.

  • Versor Investments reported no remaining Cytek Biosciences position as of Q1 2025 after selling out during the quarter.
  • Versor Investments sold 47,000 Cytek Biosciences shares in Q1 2025, an estimated $305K.
  • Versor Investments first reported a position in Cytek Biosciences in Q4 2022 and held it in 6 quarters.
  • Versor Investments's Cytek Biosciences position peaked at $315K in Q1 2024.
  • 160 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2025.

Based on Versor Investments's 13F filing for Q1 2025, filed 13 May 2025.